Authors: Argiris, A Heald, P Kuzel, T Foss, FM DiStasio, S Cooper, DL Arbuck, S Murren, JR

Citation: A. Argiris et al., Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma, INV NEW DR, 19(4), 2001, pp. 321-326

Authors: Alcindor, T Gorgun, G Miller, KB Roberts, TF Sprague, K Schenkein, DP Foss, FM

Citation: T. Alcindor et al., Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease, BLOOD, 98(5), 2001, pp. 1622-1625

Authors: Foss, FM

Citation: Fm. Foss, Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: Single-agent and combination studies, SEMIN ONCOL, 27(2), 2000, pp. 58-63

Authors: Akpek, G Koh, HK Bogen, S O'Hara, C Foss, FM

Citation: G. Akpek et al., Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma, CANCER, 86(7), 1999, pp. 1368-1376

Authors: Foss, FM Kuzel, TM

Citation: Fm. Foss et Tm. Kuzel, Novel treatment approaches for cutaneous T-cell lymphoma, CANC TREAT, 99, 1999, pp. 227-240

Authors: Foss, FM Saleh, MN Krueger, JG Nichols, JC Murphy, JR

Citation: Fm. Foss et al., Diphtheria toxin fusion proteins, CURR T MICR, 234, 1998, pp. 63-81